 <h1>Trifluoperazine Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to trifluoperazine: oral tablets</i></p><h3>Warning</h3><p><ul>
Increased Mortality in Geriatric Patients with Dementia-related Psychosis
<li>
Geriatric patients with dementia-related psychosis treated with antipsychotic agents are at an increased risk of death.&lt;sup&gt;a&lt;/sup&gt; &lt;sup&gt;e&lt;/sup&gt; &lt;sup&gt;l&lt;/sup&gt; &lt;sup&gt;m&lt;/sup&gt; &lt;sup&gt;o&lt;/sup&gt;</li></ul></p><ul>
Increased Mortality in Geriatric Patients with Dementia-related Psychosis
<li>
Geriatric patients with dementia-related psychosis treated with antipsychotic agents are at an increased risk of death.&lt;sup&gt;a&lt;/sup&gt; &lt;sup&gt;e&lt;/sup&gt; &lt;sup&gt;l&lt;/sup&gt; &lt;sup&gt;m&lt;/sup&gt; &lt;sup&gt;o&lt;/sup&gt;</li></ul><p>
<li>
Analyses of 17 placebo-controlled trials in geriatric patients mainly receiving atypical antipsychotic agents revealed an approximate 1.6- to 1.7-fold increase in mortality compared with that in patients receiving placebo.&lt;sup&gt;a&lt;/sup&gt; &lt;sup&gt;l&lt;/sup&gt; &lt;sup&gt;m&lt;/sup&gt;</li></p><p>
<li>
Most fatalities appeared to result from cardiovascular-related events (e.g., heart failure, sudden death) or infections (mostly pneumonia).&lt;sup&gt;a&lt;/sup&gt; &lt;sup&gt;m&lt;/sup&gt;</li></p><p>
<li>
Observational studies suggest that conventional or first-generation antipsychotic agents also may increase mortality in such patients.&lt;sup&gt;a&lt;/sup&gt; &lt;sup&gt;e&lt;/sup&gt; &lt;sup&gt;l&lt;/sup&gt;</li></p><p>
<li>
Antipsychotic agents, including trifluoperazine, are <i>not</i> approved for the treatment of dementia-related psychosis.&lt;sup&gt;a&lt;/sup&gt; &lt;sup&gt;l&lt;/sup&gt; &lt;sup&gt;m&lt;/sup&gt;</li></p><p></p><p>Side effects include:</p><p>Extrapyramidal reactions (e.g., Parkinson-like symptoms, dystonia, akathisia), drowsiness, fatigue, muscular weakness, insomnia, blurred vision, skin reactions or rash, anorexia, dry mouth, hypotension, amenorrhea, galactorrhea.    </p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to trifluoperazine: compounding powder, intramuscular solution, oral concentrate, oral tablet</i></p><h3>Nervous system</h3><p><b>Frequency not reported</b>: Drowsiness, dizziness, tremulousness, extrapyramidal symptoms, parkinsonism, acute dystonia/dyskinesia, facial grimacing, opisthotonos, hyperreflexia, tardive dyskinesia/tardive dyskinesia of the facial muscles, involuntary movement of the extremities, neuroleptic malignant syndrome, altered consciousness, autonomic instability, grand/petite mal convulsions, altered cerebrospinal fluid proteins, cerebral edema, headache, akathisia (with motor restlessness and difficulty sitting still)<sup>[Ref]</sup></p><p>Extrapyramidal symptoms were more common in doses of over 6 mg/day.  Symptoms included parkinsonism, torticollis, facial grimacing, trismus, tongue protrusion, abnormal eye movements, akathisia with motor restlessness and difficulty sitting still.</p><p></p><p>Acute dystonia/dyskinesia typically occurred early in treatment and was likely to be severe in children; this side effect included torticollis, facial grimacing, trismus, tongue protrusion, and abnormal eye movements.</p><p></p><p>Neuroleptic malignant syndrome was characterized by hyperpyrexia, muscle rigidity, altered consciousness and autonomic instability.</p><p></p><p>Grand/petite mal convulsions occurred in patients with/a history of EEG abnormalities.<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Frequency not reported</b>: Mild postural hypotension/hypotension, edema/peripheral edema, tachycardia, ECG changes, QT prolongation, T-wave changes, ventricular arrhythmias/fibrillation/tachycardia, atrioventricular block, paroxysmal tachycardia, serious arrhythmias, cardiac arrest, Torsade de pointes, venous thromboembolism, deep vein thrombosis, severe hypotension/fatal hypotension<sup>[Ref]</sup></p><p>Severe hypotension occurred in patients with specific medical problems (e.g., mitral insufficiency, pheochromocytoma).</p><p></p><p>ECG changes, including QT prolongation and T-wave distortions, were typically reversible and occurred in patients taking phenothiazine antipsychotics.<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Frequency not reported</b>: Skin reactions/disorders, photosensitivity reactions, skin pigmentation, epithelial keratopathy, itching/pruritus, erythema, urticaria, angioneurotic edema, erythema multiforme, contact dermatitis, eczema (up to exfoliative dermatitis)<sup>[Ref]</sup></p><p>Skin pigmentation and epithelial keratopathy occurred in patients receiving substantial doses for a prolonged duration.</p><p></p><p>Contact dermatitis occurred in patients who handled phenothiazines.<sup>[Ref]</sup></p><h3>Psychiatric</h3><p>Dulled feelings and/or agitation have occurred at low doses, especially in non-psychotic patients.<sup>[Ref]</sup></p><p><b>Frequency not reported</b>: Transient restlessness, stimulation, insomnia, confusion/toxic confusional states, feelings dulled, agitation, increased aggressiveness, withdrawal reactions, reactivation of the psychotic processes, catatonic-like states<sup>[Ref]</sup></p><h3>Other</h3><p><b>Frequency not reported</b>: Lassitude, fatigue, hyperpyrexia, sudden, unexplained death, signs of persistent infection, neonatal drug withdrawal syndrome, autonomic reactions, reversed epinephrine effect, intensification/prolongation of the action of atropine/heat/organophosphorous insecticides/central nervous system depressants (e.g., opiates, analgesics, antihistamines, barbiturates, alcohol)<sup>[Ref]</sup></p><p>Sudden death from cardiac arrest or asphyxia (cough reflex failure) has been reported in patients receiving phenothiazines.<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Frequency not reported</b>: Blood dyscrasias, agranulocytosis, pancytopenia, leukopenia, thrombocytopenia, thrombocytopenic purpura, eosinophilia, hemolytic anemia, aplastic anemia<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Frequency not reported</b>: Blurred vision, abnormal eye movements, oculogyric crisis, lenticular opacities, pigmentary retinopathy, lacrimation, keratoconjunctivitis, miosis and mydriasis, lenticular and corneal deposits<sup>[Ref]</sup></p><p>Lenticular and corneal deposits occurred in patients receiving substantial doses for a prolonged duration.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Frequency not reported</b>: Dry mouth, constipation, tongue protrusion, nausea, vomiting, obstipation, ileus/adynamic ileus, atonic colon<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Frequency not reported</b>: Urinary hesitancy/retention, lactation, galactorrhea, menstrual irregularities, false-positive pregnancy tests, amenorrhea, ejaculation disorders/impotence, priapism<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Frequency not reported</b>: Muscular weakness, torticollis, trismus, muscle rigidity, systemic lupus erythematosus-like syndrome<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Frequency not reported</b>: Anorexia, weight gain/change, hyperglycemia, hypoglycemia, increased appetite<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Frequency not reported</b>: Pulmonary embolism, nasal congestion, asthma, bronchospasm, laryngeal edema<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Frequency not reported</b>: Mild cholestatic jaundice, liver damage, jaundice, biliary stasis<sup>[Ref]</sup></p><h3>Endocrine</h3><p>Hyperprolactinemia occurred in patients given higher doses, and was associated with the development of galactorrhea, amenorrhea, and/or gynecomastia.<sup>[Ref]</sup></p><p><b>Frequency not reported</b>: Gynecomastia, hyperprolactinemia/elevated prolactin levels, endocrine disturbances<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Frequency not reported</b>: Other allergic reactions, anaphylaxis/anaphylactoid reactions<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Frequency not reported</b>: Hormone-dependent breast neoplasms<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Frequency not reported</b>: Glycosuria<sup>[Ref]</sup></p><p id="ref_1">1. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_2">2. "Product Information. Stelazine (trifluoperazine)" SmithKline Beecham, Philadelphia, PA. </p><p id="ref_3">3. "Product Information. Stelazine (trifluoperazine)" SmithKline Beecham, Philadelphia, PA. </p><p id="ref_4">4. Cerner Multum,  Inc. "Australian Product Information." O 0</p><h2>More about trifluoperazine</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>16 Reviews</li>
<li>Drug class: phenothiazine antipsychotics</li>
<li>FDA Alerts (2)</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Anxiety</li>
<li>Schizophrenia</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>